Journal
ACS NANO
Volume 11, Issue 1, Pages 12-18Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.6b08244
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA194058, HHSN261200800001E, R01 CA188743] Funding Source: Medline
- NIBIB NIH HHS [R13 EB021826, R01 EB022040] Funding Source: Medline
- NIEHS NIH HHS [R01 ES024681] Funding Source: Medline
- CCR NIH HHS [HHSN261200800001C] Funding Source: Medline
Ask authors/readers for more resources
Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: Mechanisms and Barriers in Nanomedicine. The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available